Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

NCT06867536 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lymphoma

Interventions

DRUG: Glofitamab + Obinutuzumab

Sponsor

Liling Zhang